✦ LIBER ✦

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

✍ Scribed by Ravinder Maini; E William St Clair; Ferdinand Breedveld; Daniel Furst; Joachim Kalden; Michael Weisman; Josef Smolen; Paul Emery; Gregory Harriman; Marc Feldmann; Peter Lipsky

Book ID: 117312927
Publisher: The Lancet
Year: 1999
Tongue: English
Weight: 133 KB
Volume: 354
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(99)05246-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised double-blind comparison of ch

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

✍ M.J Elliott; R.N Maini; M Feldmann; J.R Kalden; C Antoni; J.S Smolen; B Leeb; F. 📂 Article 📅 1994 🏛 The Lancet 🌐 English ⚖ 797 KB

Double-blind, placebo-controlled multice

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-cd4 antibody, cm-t412, in rheumatoid arthritis patients receiving concomitant methotrexate

✍ Larry W. Moreland; Parks W. Pratt; Maureen D. Mayes; Arnold Postlethwaite; Micha 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

Adalimumab, a fully human anti–tumor nec

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

✍ Michael E. Weinblatt; Edward C. Keystone; Daniel E. Furst; Larry W. Moreland; Mi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Golimumab in patients with active rheuma

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

✍ Josef S Smolen; Jonathan Kay; Mittie K Doyle; Robert Landewé; Eric L Matteson; J 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 222 KB

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra